Sivik Global Healthcare LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 20,000 shares of the medical instruments supplier's stock, valued at approximately $3,881,000. Becton, Dickinson and Company comprises approximately 1.1% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 24th biggest holding.
Other large investors have also recently bought and sold shares of the company. Activest Wealth Management raised its stake in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company during the 3rd quarter valued at $25,000. SOA Wealth Advisors LLC. raised its stake in Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 95 shares during the last quarter. Accredited Wealth Management LLC raised its stake in Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 70 shares during the last quarter. Finally, Cornerstone Planning Group LLC raised its stake in Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 139 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company's stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares of the company's stock, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,713 shares of company stock valued at $536,881 over the last three months. 0.40% of the stock is currently owned by insiders.
Analysts Set New Price Targets
BDX has been the subject of several research analyst reports. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Wells Fargo & Company lowered their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 10th. Piper Sandler restated a "neutral" rating and set a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Jefferies Financial Group lowered their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating on the stock in a research report on Tuesday, February 10th. Finally, Bank of America boosted their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a "neutral" rating in a research report on Monday, January 5th. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $191.62.
View Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Down 0.3%
NYSE BDX opened at $154.87 on Wednesday. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The stock's 50 day moving average is $173.75 and its two-hundred day moving average is $186.01. The company has a market capitalization of $44.10 billion, a price-to-earnings ratio of 25.26, a PEG ratio of 11.20 and a beta of 0.29. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts' consensus estimates of $2.81 by $0.10. The company had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company's quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the business earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are often a sign that the company's leadership believes its stock is undervalued.
Becton, Dickinson and Company Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, March 10th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 68.52%.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of ten stocks that are set to soar in 2026, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
